Sumatriptan contraindications

List of contraindications
Cardiac/cerebrovascular/eripheral vascular syndromes Uncontrolled hypertension MAO-A inhibitors Ergotamine-containing/ergot-type medication Hemiplegic/basilar migraine Hypersensitivity to sumatriptan Severe hepatic impairment

Cardiac/cerebrovascular/eripheral vascular syndromes
Imitrex Nasal Spray should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive Imitrex Nasal Spray. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease. Return to top

Uncontrolled hypertension
Because Imitrex Nasal Spray may increase blood pressure, it should not be given to patients with uncontrolled hypertension. Return to top

MAO-A inhibitors
Concurrent administration of MAO-A inhibitors or use within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated. Return to top

Ergotamine-containing/ergot-type medication
IMITREX Nasal Spray and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should Imitrex Nasal Spray and another 5-HT1 agonist. Return to top

Hemiplegic/basilar migraine
Imitrex Nasal Spray should not be administered to patients with hemiplegic or basilar migraine. Return to top

Hypersensitivity to sumatriptan
Imitrex Nasal Spray is contraindicated in patients with hypersensitivity to sumatriptan or any of its components. Return to top

Severe hepatic impairment
IMITREX Nasal Spray is contraindicated in patients with severe hepatic impairment. Return to top